Overview

Price chart · mood · technical indicators

ESPR

Esperion Therapeutics Incstock Healthcare

Drug Manufacturers - Specialty & Generic

$3.12219.84%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$0.69$4.18

Current: $3.12

Idea: EMA

1Y Return

+128.7%

Sharpe 3Y

0.86

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

ESPR

+219.84%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—Forward 4.64

EPS (TTM)$-0.110.0% YoY

Profit margin-5.6%HEALTHCARE

Market cap$800.5MSmall cap

Wall Street coverage

$3.82median target· current $2.12 (+80.2%)8 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 4.64
PEG ratio: -4.78
P/B: 98.42
P/S (TTM): 1.99
EV/EBITDA: 13.86

Profitability & growth

ROE (TTM): -260.8%
Operating margin: 50.6%
Revenue growth YoY: 143.7%
Dividend yield: —
Beta: 1.17

Last earnings

Feb 24, 2026 · Estimate $0.29 · Reported $0.22

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Esperion Therapeutics Inc

Company profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 3891 RANCHERO DRIVE, ANN ARBOR, MI
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$800.5M

Shares outstanding$257.4M

52W high$4.18

52W low$0.69

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

ESPR

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Esperion to be Acquired by ARCHIMED

Ademi LLP Investigates Whether Esperion Therapeutics, Inc. Is Obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs

ESPR Rallies As Royalty Deal Fuels Corstasis Expansion

Rumor Desk: ESPERION PARTNERSHIP WITH BIG PHARMA IN THE WORKS. Stock Price Will Double

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion sets May 7 earnings release, 8 a.m. ET webcast

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion to Report First Quarter 2026 Financial Results on May 7

First quarter 2026 results set for May 7 as Esperion Therapeutics outlines earnings calendar

Esperion to Report First Quarter 2026 Financial Results on May 7

Wasatch Advisors takes 6.1% stake in Esperion Therapeutics (NASDAQ: ESPR)

Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management

[ARS] Esperion Therapeutics, Inc. SEC Filing

Esperion Therapeutics Target of Unusually Large Options Trading (NASDAQ:ESPR)

About Esperion Therapeutics Inc

Classification

Company profile

ESPR

Market Comparison

ESPR Market Analysis

Overview

ESPR

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Esperion to be Acquired by ARCHIMED

Ademi LLP Investigates Whether Esperion Therapeutics, Inc. Is Obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs

ESPR Rallies As Royalty Deal Fuels Corstasis Expansion

Rumor Desk: ESPERION PARTNERSHIP WITH BIG PHARMA IN THE WORKS. Stock Price Will Double

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion sets May 7 earnings release, 8 a.m. ET webcast

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion to Report First Quarter 2026 Financial Results on May 7

First quarter 2026 results set for May 7 as Esperion Therapeutics outlines earnings calendar

Esperion to Report First Quarter 2026 Financial Results on May 7

Wasatch Advisors takes 6.1% stake in Esperion Therapeutics (NASDAQ: ESPR)

Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management

[ARS] Esperion Therapeutics, Inc. SEC Filing

Esperion Therapeutics Target of Unusually Large Options Trading (NASDAQ:ESPR)

About Esperion Therapeutics Inc

Classification

Company profile

ESPR

Market Comparison